| Oncogenic KRAS impairs EGFR antibodies efficiency by C/EBPbeta-dependent suppression of EGFR expression. | None |
| Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1. | None |
| Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. | None |
| Activation of beta-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response. | None |
| Our data highlights a new functional synergism between oncogenic EGFR and PIK3CA with WNT/beta-catenin conferring high tolerance to oxidative stress generated by nutrient deprivation. | None |
| Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops. | None |
| Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. | None |
| Oncogenic cooperation between SOCS family proteins and EGFR identified using a Drosophila epithelial transformation model. | None |
| ERBB oncogene proteins as targets for monoclonal antibodies. | None |
| Tissue samples burdened with specific oncogen signatures like EGFR gene amplification could be detected in precancerous lesion. This might improve follow-up and treatment protocols of glottic lesions | None |
| EGFR, which is the product of a well-characterized oncogene in human cancers, suppresses the maturation of specific tumour-suppressor-like miRNAs in response to hypoxic stress through phosphorylation of argonaute 2 (AGO2) at Tyr 393 | None |
| EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. | None |
| A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. | None |
| Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B. | None |
| Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference. | None |
| Our findings highlight the importance of the polybasic juxtamembrane sequence in regulating the oncogenic potential of EGFR signaling. | None |
| A comparative survey of functional footprints of EGFR pathway mutations in human cancers. | None |
| Global functional profiles show that tumors driven by the EGFR oncogene often display an inflammatory response signature depending on the tissue type. | None |
| Characterization of the epidermal growth factor receptor and the erbB oncogene product by site-specific antibodies. | None |
| Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. | None |